STOCK TITAN
  1. Home
  2. News
  3. HUGE

FSD Pharma Inc - HUGE STOCK NEWS

Welcome to our dedicated news page for FSD Pharma (Ticker: HUGE), a resource for investors and traders seeking the latest updates and insights on FSD Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FSD Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FSD Pharma's position in the market.

News
FSD Pharma Provides Update from Celly Nu’s Partnership with Six+One for unbuzzd(TM)
Rhea-AI Summary
FSD Pharma provides an update on Celly Nu's partnership with Six+One for unbuzzd(TM), a new innovative beverage product designed to support the body's natural processes. Celly Nu announced a strategic partnership with Six+One to enhance the presence of unbuzzd(TM) in the US market, leveraging Six+One's branding expertise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
News
FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)
Rhea-AI Summary
FSD Pharma provides an update on Celly Nu's anticipated launch of unbuzzd(TM), a scientifically formulated beverage product designed to support alcohol metabolism and alertness. Celly Nu partners with BevSource for production and distribution in the US. The partnership includes various services to ensure a successful launch. The product, unbuzzd(TM), features a blend of vitamins, minerals, and botanical extracts. Industry veterans like Gerry David and John Duffy lead the project, supported by Kevin Harrington.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.78%
Tags
none
-
News
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
Rhea-AI Summary
FSD Pharma, a biopharmaceutical company, expands its pipeline to include potential weight loss and liver health formulations and products. The company is investigating ingredients and dietary supplements to promote weight loss, liver health, and faster alcohol metabolism. This move aims to address metabolic disorders and create a new product line.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.8%
Tags
none
News
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption
Rhea-AI Summary
FSD Pharma increases investment in Celly Nutrition Corp. to launch a product expediting alcohol metabolism and recovery. The loan agreement allows for the principal increase by $300,000, deferral of interest payments, and potential conversion to common shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.4%
Tags
none
-
News
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Rhea-AI Summary
FSD Pharma Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, giving them a 180-day compliance period to meet the requirement or face potential delisting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
none
-
News
FSD Pharma Announces Filing of Year-End 2023 Results
Rhea-AI Summary
FSD Pharma Inc. (HUGE) announces the filing of audited annual financial results for the fourth quarter and full year ended December 31, 2023, along with the Annual Report on 20-F for the same period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.18%
Tags
none
News
FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
Rhea-AI Summary
FSD Pharma Inc. announces a partnership with iNGENu CRO Pty to conduct a Phase 1 clinical study on Lucid-21-302, a novel compound for treating multiple sclerosis. The compound has shown promise in preclinical models for preventing demyelination, a key factor in MS and other neurogenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
clinical trial
-
News
FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)
Rhea-AI Summary
FSD Pharma Inc. announces the submission of a Clinical Trial Application for a Phase-1b clinical trial to assess the safety and efficacy of unbuzzd™ in Healthy Volunteers in an Induced State of Alcohol Intoxication. The trial aims to evaluate the potential benefits of unbuzzd™, a dietary supplement product, in enhancing cognition, replenishing cofactors needed for alcohol metabolism, and accelerating the rate of alcohol metabolism in the body. The company is working closely with Australian partners and an ethics committee for the project. John Duffy, CEO of Celly Nutrition, highlighted the product's ability to restore mental alertness and improve cognition post-alcohol consumption, emphasizing the science-based approach. The involvement of industry veterans from companies like Coca-Cola and Celsius Energy drink adds credibility to the project.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
clinical trial
-
News
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
Rhea-AI Summary
FSD Pharma announces positive results from Phase-1 clinical study on Lucid-21-302 for Multiple Sclerosis treatment at ACTRIMS 2024 Forum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
none
News
FSD Pharma Announces Debt Settlement
Rhea-AI Summary
FSD Pharma Inc. settles $637,650 in debts through share issuance and grants RSUs to consultants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags
none
Stock HUGE logo
FSD Pharma Inc

Nasdaq:HUGE

HUGE Rankings

#5158 Ranked by Market Cap
#1071 Ranked by Stock Gains
N/A Ranked by Dividends

HUGE Stock Data

24.24M
34.34M
17.37%
2.53%
0.82%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Canada
Toronto

About HUGE

fsd pharma inc., through its subsidiary, fv pharma inc., produces medical cannabis in canada. the company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, gi tract, and musculoskeletal system, such as chronic pain. fsd pharma inc. has strategic alliance agreements with scicann therapeutics inc., canntab therapeutics, and solarvest bioenergy inc. the company was founded in 1998 and is headquartered in toronto, canada.